Supernus PharmaceuticalsLTS:0LB2 88 Net Current Asset Value is $5.30 as of Mar. 2026, which is 73% below its 10-year median of 19.69. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $38.86 (Modestly Overvalued). Among 609 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 67.32% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Supernus Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was $5.30.
The historical rank and industry rank for Supernus Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
LTS:0LB2'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.21 Med: 19.69 Max: 517.57
Current: 9.07
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Supernus Pharmaceuticals was 517.57. The lowest was 4.21. And the median was 19.69.
LTS:0LB2's Price-to-Net-Current-Asset-Value is ranked worse than 67.32% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.72
vs LTS:0LB2: 9.07
Supernus Pharmaceuticals (LTS:0LB2) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Supernus Pharmaceuticals Net Current Asset Value Related Terms
Supernus Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Supernus Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Net Current Asset Value Chart
LTS:0LB2 vs BCRX, PBH, RGC: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $5.30 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Net Current Asset Value of $5.30 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Supernus Pharmaceuticals and its competitors. This is 73% below median its historical median of 19.69. Over the past decade, Supernus Pharmaceuticals' Net Current Asset Value has ranged from 4.21 to 517.57. According to the industry distribution chart, Supernus Pharmaceuticals ranks #410 out of 609 companies in the Drug Manufacturers industry, placing it in the top 67.3%.
Is Supernus Pharmaceuticals' Net Current Asset Value too high?
Supernus Pharmaceuticals' current Net Current Asset Value of $5.30 is 73% below median its 10-year median of 19.69. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 517.57. The Drug Manufacturers industry median Net Current Asset Value is 5.72. Supernus Pharmaceuticals' value of $5.30 is 7.3% below this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #410 out of 609 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Net Current Asset Value compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #410 out of 609 companies for Net Current Asset Value. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 5.72. Supernus Pharmaceuticals' value of $5.30 is 7.3% below this benchmark. Historically, Supernus Pharmaceuticals' own Net Current Asset Value has ranged from 4.21 to 517.57 over the past decade. While the company's 10-year median is 19.69 vs. the industry median of 5.72, Supernus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.72, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Net Current Asset Value of $5.30 is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Net Current Asset Value is $5.30, which is 73% below median its own 10-year median of 19.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $38.86, compared to a current price of $47.23 — trading 21.5% above its estimated fair value. The current Net Current Asset Value is $5.30, which is 73% below median its 10-year median of 19.69 and 7.3% below the Drug Manufacturers industry median of 5.72. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Net Current Asset Value is $5.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $47.23 is trading 21.5% above its estimated GF Value™ of $38.86.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Net Current Asset Value: $5.30 (73% below median its 10-year median of 19.69)
GF Value™: $38.86 vs. price of $47.23 (21.5% above fair value)
Industry Position: 7.3% below the Drug Manufacturers median (#410 of 609)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
